Revance Therapeutics (RVNC) Scheduled to Post Earnings on Thursday

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, May 9th. Analysts expect Revance Therapeutics to post earnings of ($0.66) per share for the quarter. Investors that wish to register for the company's conference call can do so using this link.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last issued its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.17. The business had revenue of $69.80 million during the quarter, compared to the consensus estimate of $64.02 million. On average, analysts expect Revance Therapeutics to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Revance Therapeutics Stock Up 4.8 %

RVNC stock traded up $0.18 during midday trading on Friday, reaching $3.95. The company's stock had a trading volume of 1,370,339 shares, compared to its average volume of 1,813,674. The business's 50-day simple moving average is $4.82 and its 200-day simple moving average is $6.31. Revance Therapeutics has a 52 week low of $3.21 and a 52 week high of $37.98. The stock has a market cap of $411.65 million, a PE ratio of -1.04 and a beta of 1.16.

Insider Buying and Selling

In related news, insider Dwight Moxie sold 8,125 shares of the company's stock in a transaction on Monday, March 18th. The shares were sold at an average price of $5.04, for a total value of $40,950.00. Following the completion of the transaction, the insider now directly owns 137,815 shares of the company's stock, valued at approximately $694,587.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, insider Dwight Moxie sold 8,125 shares of Revance Therapeutics stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total value of $40,950.00. Following the sale, the insider now owns 137,815 shares of the company's stock, valued at approximately $694,587.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Tobin Schilke sold 9,361 shares of the company's stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $5.04, for a total value of $47,179.44. Following the transaction, the chief financial officer now directly owns 192,666 shares of the company's stock, valued at approximately $971,036.64. The disclosure for this sale can be found here. Insiders have sold a total of 29,089 shares of company stock worth $143,642 over the last ninety days. Company insiders own 5.10% of the company's stock.

Analyst Upgrades and Downgrades

RVNC has been the topic of several analyst reports. Mizuho lowered Revance Therapeutics from a "buy" rating to a "neutral" rating and cut their target price for the company from $16.00 to $9.00 in a research note on Monday, January 29th. The Goldman Sachs Group lifted their price objective on shares of Revance Therapeutics from $8.00 to $9.00 and gave the stock a "neutral" rating in a research note on Friday, March 1st. Barclays lowered their target price on shares of Revance Therapeutics from $35.00 to $10.00 and set an "overweight" rating for the company in a research note on Monday, January 29th. Piper Sandler reduced their price target on shares of Revance Therapeutics from $42.00 to $20.00 and set an "overweight" rating on the stock in a research report on Thursday, February 29th. Finally, HC Wainwright restated a "buy" rating and issued a $12.00 price objective on shares of Revance Therapeutics in a research report on Thursday, February 29th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, Revance Therapeutics presently has a consensus rating of "Hold" and an average price target of $13.75.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.